These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31871301)

  • 1. Everolimus Inhibits the Progression of Ductal Carcinoma
    Chen G; Ding XF; Pressley K; Bouamar H; Wang B; Zheng G; Broome LE; Nazarullah A; Brenner AJ; Kaklamani V; Jatoi I; Sun LZ
    Clin Cancer Res; 2020 Mar; 26(6):1486-1496. PubMed ID: 31871301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
    Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
    Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
    Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
    Wahler J; So JY; Kim YC; Liu F; Maehr H; Uskokovic M; Suh N
    Cancer Prev Res (Phila); 2014 Jun; 7(6):617-26. PubMed ID: 24691501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma
    Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q
    J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.
    Duivenvoorden HM; Rautela J; Edgington-Mitchell LE; Spurling A; Greening DW; Nowell CJ; Molloy TJ; Robbins E; Brockwell NK; Lee CS; Chen M; Holliday A; Selinger CI; Hu M; Britt KL; Stroud DA; Bogyo M; Möller A; Polyak K; Sloane BF; O'Toole SA; Parker BS
    J Pathol; 2017 Dec; 243(4):496-509. PubMed ID: 29086922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer.
    Citron F; Segatto I; Vinciguerra GLR; Musco L; Russo F; Mungo G; D'Andrea S; Mattevi MC; Perin T; Schiappacassi M; Massarut S; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B
    Cancer Res; 2020 Mar; 80(5):1064-1077. PubMed ID: 31862778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.
    Treekitkarnmongkol W; Shah V; Kai K; Katayama H; Wong J; Ladha FA; Nguyen T; Menegaz B; Lu W; Yang F; Mino B; Tang X; Gagea M; Batra H; Raso MG; Wistuba II; Krishnamurthy S; Pinder SE; Sawyer EJ; Thompson AM; Sen S
    Br J Cancer; 2024 Jul; 131(1):171-183. PubMed ID: 38760444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.
    Bi X; Hameed M; Mirani N; Pimenta EM; Anari J; Barnes BJ
    Breast Cancer Res; 2011; 13(6):R111. PubMed ID: 22053985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS).
    Farnie G; Johnson RL; Williams KE; Clarke RB; Bundred NJ
    Cell Cycle; 2014; 13(3):418-25. PubMed ID: 24247151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model.
    Valdez KE; Fan F; Smith W; Allred DC; Medina D; Behbod F
    J Pathol; 2011 Dec; 225(4):565-73. PubMed ID: 22025213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.